Dapagliflozin for Renal Protection in Heart Transplant Recipients: A Randomized Clinical Trial
Circulation · 08.11.2026
DOI: 10.1161/circulationaha.126.083760 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, online erschienen am 08.11.2026. Verfasst von Stine Holmen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Innlandet Hospital Trust, Hamar, Norway; Institute of Clinical Medi…. Gefördert von: Oslo universitetssykehus HF, Nasjonalforeningen for Folkehelsen, Kardimmun foundation.
Abstract (Originalsprache)
Background
Progressive kidney disease is common in heart transplant recipients due to calcineurin inhibitor exposure and pre-existing comorbidities. Sodium–glucose cotransporter-2 (SGLT2) inhibitors may attenuate the decline in kidney function, but evidence in heart transplant recipients is limited.
Methods
The DAPAgliflozin for Renal protection in Heart Transplant recipients (DAPARHT) trial is a multicenter, double-blind, randomized, placebo-controlled trial conducted at six heart transplant centers in Northern Europe. We randomized adult heart transplant recipients with an estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m ² at least one year after transplantation 1:1 to receive dapagliflozin 10 mg or matching placebo once daily. The primary endpoint was the slope of the eGFR from 2 weeks after treatment initiation to the end of the 12-month blinded treatment period.
Results
Between June 2022 and September 2025, we randomized 430 participants, of whom 217 were allocated to dapagliflozin and 213 were allocated to placebo. We included the 424 patients with at least one eGFR measurement after baseline in the full analysis set. Their mean age was 53 ± 14 years and 29& were women. The eGFR at baseline was 67 ± 22 mL/min/1.73 m 2 . The median time from transplantation was 7 (3 – 13) years. Dapagliflozin improved the chronic slope of the eGFR compared with placebo. The change in the eGFR from 2 weeks to 12 months after treatment initiation was 2.0 (95% confidence interval [CI] 1.0 – 3.1) mL/min/1.73 m 2 in the dapagliflozin group and 0.3 (95% CI -0.8 – 1.4) mL/min/1.73 m 2 in the placebo group for a between-group difference of 1.7 (95% confidence interval 0.1 – 3.3) mL/min/1.73 m ² ; p = 0.03. There were no unexpected safety signals and similar rates of adverse events, including infections, between groups.
Conclusions
In heart transplant recipients, dapagliflozin, compared with placebo, improved the slope of the eGFR from 2 weeks to 12 months of treatment.
Autor:innen und Institutionen
- Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Innlandet Hospital Trust, Hamar, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
- Department of Cardiology, Cardiovascular Institute, Erasmus Medical Center, Rotterdam, the Netherlands; Erasmus Medical Center Transplant Institute, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherland…
- University of Groningen, Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands.
- Department of Medicine Solna, Karolinska Institutet, MU of Cardiology, Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.
- Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands; Transplantation Center Utrecht, Utrecht, the Netherlands.
- Cardiology, Department of Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden.
ORCID-Profile: Stine Holmen, Olivier Manintveld, Kevin Damman, Ida Haugen Löfman, Mariusz Szymanski, Oscar Braun, Martin Lando, Jasper J Brugts, Yannick J H J Taverne, Jozine M Ter Maaten, Michael Melin, Manon G van der Meer, Håvard Ravnestad, Kaspar Broch
Förderung
- Oslo universitetssykehus HF
- Nasjonalforeningen for Folkehelsen
- Kardimmun foundation
- AZ | AstraZeneca Mölndal
Zitieren
APA
Holmen, S., Manintveld, O., Damman, K., Haugen Löfman, I., Szymanski, M., Braun, O., Lando, M., Bjørkelund, E., Brugts, J. J., Taverne, Y. J. H. J., Ter Maaten, J. M., Thorvaldsen, T., Melin, M., van der Meer, M. G., Fagerland, M. W., Ravnestad, H., Gude, E., Andreassen, A. K., Gullestad, L., & Broch, K. (2026). Dapagliflozin for Renal Protection in Heart Transplant Recipients: A Randomized Clinical Trial. Circulation. https://doi.org/10.1161/circulationaha.126.083760
Vancouver
Holmen S, Manintveld O, Damman K, Haugen Löfman I, Szymanski M, Braun O, et al. Dapagliflozin for Renal Protection in Heart Transplant Recipients: A Randomized Clinical Trial. Circulation. 2026. doi:10.1161/circulationaha.126.083760
BibTeX
@article{Holmen2026,
author = {Holmen, Stine and Manintveld, Olivier and Damman, Kevin and Haugen Löfman, Ida and Szymanski, Mariusz and Braun, Oscar and Lando, Martin and Bjørkelund, Elisabeth and Brugts, Jasper J and Taverne, Yannick J H J and Ter Maaten, Jozine M and Thorvaldsen, Tonje and Melin, Michael and van der Meer, Manon G and Fagerland, Morten W and Ravnestad, Håvard and Gude, Einar and Andreassen, Arne K and Gullestad, Lars and Broch, Kaspar},
title = {Dapagliflozin for Renal Protection in Heart Transplant Recipients: A Randomized Clinical Trial},
journal = {Circulation},
year = {2026},
doi = {10.1161/circulationaha.126.083760}
}
EUVIMED